# A Study of SHR-1802 in Patients With Advanced Solid Tumor

> **NCT05208177** · PHASE2 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SHR-1802＋camrelizumab + famitinib

## Key facts

- **NCT ID:** NCT05208177
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-22
- **Primary completion:** 2023-08-18
- **Final completion:** 2023-08-18
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Adjustment of R\&D strategy
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05208177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05208177, "A Study of SHR-1802 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05208177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*